Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACRX Stock Summary
In the News
ACRX Financial details
Company Rating
Neutral
Market Cap
14.58M
Income
-7.88M
Revenue
622K
Book val./share
1.09
Cash/share
0.8
Dividend
-
Dividend %
-
Employees
19
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-1.83
Forward P/E
-
PEG
0.16
P/S
23.44
P/B
0.79
P/C
1.15
P/FCF
-0.68
Quick Ratio
3.75
Current Ratio
4.04
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1
EPS next Y
-
EPS next Q
-
EPS this Y
-100.01%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-86.09%
Revenue last 5Y
-22.23%
Revenue Q/Q
-53.75%
EPS Q/Q
-79.75%
-
-
-
-
SMA20
35.06%
SMA50
103.92%
SMA100
-
Inst Own
0.02%
Inst Trans
0%
ROA
-34%
ROE
-49%
ROC
-0.74%
Gross Margin
42%
Oper. Margin
-2336%
Profit Margin
-1266%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.425-2.3
52W High
-
52W Low
-
RSI
49.8
Rel Volume
0.5
Avg Volume
138.82K
Volume
70.03K
Perf Week
-11.35%
Perf Month
22.12%
Perf Quarter
-
Perf Half Y
43.84%
-
-
-
-
Beta
0.517
-
-
Volatility
0.08%, 0.13%
Prev Close
-1.91%
Price
0.922
Change
-12.19%
ACRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.58 | 1.27 | 0.47 | 0.24 | 0 | |
Net income per share | -13.45 | -9.47 | -5.86 | 6.45 | 0 | |
Operating cash flow per share | -12.93 | -9.03 | -5.01 | -3.82 | 0 | |
Free cash flow per share | -13.8 | -9.47 | -5.31 | -3.87 | 0 | |
Cash per share | 16.7 | 10.06 | 8.62 | 2.13 | 0 | |
Book value per share | -10.46 | -13.08 | -5.99 | 2.95 | 0 | |
Tangible book value per share | -10.46 | -13.08 | -5.99 | 1.75 | 0 | |
Share holders equity per share | -10.46 | -13.08 | -5.99 | 2.95 | 0 | |
Interest debt per share | 7.82 | 6.78 | 3.49 | 1.56 | 0 | |
Market cap | 167.08M | 105.72M | 67.12M | 16.74M | 10.48B | |
Enterprise value | 182.15M | 104.04M | 73.08M | 11.89M | 10.48B | |
P/E ratio | -3.14 | -2.62 | -1.91 | 0.35 | -1.02K | |
Price to sales ratio | 72.99 | 19.52 | 23.82 | 9.45 | 16.1K | |
POCF ratio | -3.26 | -2.75 | -2.24 | -0.59 | -599.35 | |
PFCF ratio | -3.06 | -2.62 | -2.11 | -0.58 | -595.94 | |
P/B Ratio | -4.03 | -1.9 | -1.87 | 0.77 | 743.27 | |
PTB ratio | -4.03 | -1.9 | -1.87 | 0.77 | 743.27 | |
EV to sales | 79.58 | 19.21 | 25.93 | 6.71 | 16.1K | |
Enterprise value over EBITDA | -3.5 | -2.81 | -2.37 | -0.39 | -620.41 | |
EV to operating cash flow | -3.56 | -2.7 | -2.44 | -0.42 | -599.02 | |
EV to free cash flow | -3.33 | -2.58 | -2.3 | -0.41 | -595.62 | |
Earnings yield | -0.32 | -0.38 | -0.52 | 2.85 | 0 | |
Free cash flow yield | -0.33 | -0.38 | -0.47 | -1.71 | 0 | |
Debt to equity | -0.72 | -0.46 | -0.52 | 0.48 | 0 | |
Debt to assets | 0.33 | 0.39 | 0.24 | 0.22 | 0 | |
Net debt to EBITDA | -0.29 | 0.05 | -0.19 | 0.16 | 0.34 | |
Current ratio | 5.27 | 2.66 | 3 | 1.78 | 2.56 | |
Interest coverage | -45.25 | -12.39 | -15.7 | -31.77 | 126.04 | |
Income quality | 0.96 | 0.95 | 0.85 | -0.59 | 0.95 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | -0.01 | 0 | 0 | |
Sales general and administrative to revenue | 19.19 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 2.04 | 0.74 | 1.45 | 2.93 | 8.52 | |
Intangibles to total assets | 0 | 0 | 0 | 0.19 | 0 | |
Capex to operating cash flow | 0.07 | 0.05 | 0.06 | 0.01 | 0.01 | |
Capex to revenue | -1.52 | -0.34 | -0.65 | -0.21 | -0.15 | |
Capex to depreciation | -2.08 | -1 | -0.93 | -0.22 | -0.32 | |
Stock based compensation to revenue | 2.21 | 0.82 | 1.64 | 1.63 | 2.66 | |
Graham number | 56.26 | 52.79 | 28.09 | 20.67 | 0 | |
ROIC | 7.69 | 1.55 | 2.89 | -0.99 | -1.2 | |
Return on tangible assets | -0.58 | -0.61 | -0.45 | 1.24 | -0.5 | |
Graham Net | -16.32 | -18.27 | -10.26 | -1.23 | 0 | |
Working capital | 58.08M | 29.2M | 36.98M | 10.8M | 7.04M | |
Tangible asset value | -41.42M | -55.75M | -35.89M | 13M | 14.11M | |
Net current asset value | -61.09M | -75.22M | -58.3M | -1.11M | 5.27M | |
Invested capital | -0.72 | -0.46 | -0.52 | 0.48 | 0 | |
Average receivables | 460.5K | 577.5K | 397.5K | 234.5K | 154.5K | |
Average payables | 1.9M | 2.23M | 2.43M | 2.08M | 1.69M | |
Average inventory | 2.07M | 2.46M | 1.37M | 1.14M | 589K | |
Days sales outstanding | 82.92 | 42.79 | 20.72 | 63.68 | 0 | |
Days payables outstanding | 92.24 | 165.62 | 206.28 | 287.38 | 0 | |
Days of inventory on hand | 176.71 | 98.39 | 108.05 | 165.95 | 0 | |
Receivables turnover | 4.4 | 8.53 | 17.61 | 5.73 | 0 | |
Payables turnover | 3.96 | 2.2 | 1.77 | 1.27 | 0 | |
Inventory turnover | 2.07 | 3.71 | 3.38 | 2.2 | 0 | |
ROE | 1.29 | 0.72 | 0.98 | 2.19 | -0.73 | |
Capex per share | -0.88 | -0.44 | -0.3 | -0.05 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.07 | 0.03 | 0 | 0.02 | 0.01 | |
Net income per share | -0.91 | -1.01 | 0.49 | -0.4 | -0.08 | |
Operating cash flow per share | -0.71 | -0.73 | -0.48 | -0.49 | -0.18 | |
Free cash flow per share | -0.73 | -0.74 | -0.49 | -0.49 | -0.18 | |
Cash per share | 2.16 | 2.13 | 1.23 | 0.68 | 0.8 | |
Book value per share | 3.73 | 2.95 | 1.31 | 0.95 | 1.09 | |
Tangible book value per share | 2.54 | 1.75 | 0.5 | 0.15 | 0.57 | |
Share holders equity per share | 3.73 | 2.95 | 1.31 | 0.95 | 1.09 | |
Interest debt per share | 1.72 | 1.43 | 0.32 | 0.04 | 0 | |
Market cap | 30.98M | 16.74M | 7.19M | 12.13M | 9.72M | |
Enterprise value | 30.73M | 11.89M | -2.79M | 4.72M | -3.67M | |
P/E ratio | -1.15 | -0.56 | 0.34 | -0.69 | -1.79 | |
Price to sales ratio | 61.11 | 66.43 | 0 | 47.93 | 83.07 | |
POCF ratio | -5.92 | -3.09 | -1.37 | -2.27 | -3.28 | |
PFCF ratio | -5.74 | -3.07 | -1.34 | -2.27 | -3.28 | |
P/B Ratio | 1.13 | 0.77 | 0.5 | 1.16 | 0.53 | |
PTB ratio | 1.13 | 0.77 | 0.5 | 1.16 | 0.53 | |
EV to sales | 60.61 | 47.17 | 0 | 18.64 | -31.36 | |
Enterprise value over EBITDA | -5.06 | -1.64 | -6.28 | -1.2 | 2.59 | |
EV to operating cash flow | -5.87 | -2.2 | 0.53 | -0.88 | 1.24 | |
EV to free cash flow | -5.69 | -2.18 | 0.52 | -0.88 | 1.24 | |
Earnings yield | -0.22 | -0.45 | 0.74 | -0.36 | -0.14 | |
Free cash flow yield | -0.17 | -0.33 | -0.74 | -0.44 | -0.3 | |
Debt to equity | 0.45 | 0.48 | 0.24 | 0 | 0 | |
Debt to assets | 0.26 | 0.22 | 0.13 | 0 | 0 | |
Net debt to EBITDA | 0.04 | 0.67 | -22.44 | 1.89 | 9.46 | |
Current ratio | 1.57 | 1.78 | 1.83 | 2.09 | 4.04 | |
Interest coverage | -26.85 | -39.33 | 1.54 | -8.7 | 0 | |
Income quality | 0.78 | 0.72 | 0.64 | 1.22 | 2.18 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 2.58 | 4.07 | 0 | 6.13 | 10.07 | |
Intangibles to total assets | 0.18 | 0.19 | 0.34 | 0.5 | 0.38 | |
Capex to operating cash flow | 0.03 | 0.01 | 0.02 | 0 | 0 | |
Capex to revenue | -0.31 | -0.19 | 0 | 0 | 0 | |
Capex to depreciation | -0.37 | -0.14 | -0.38 | 0 | 0 | |
Stock based compensation to revenue | 1.38 | 2.59 | 0 | 1.86 | 3.23 | |
Graham number | 8.77 | 8.18 | 3.8 | 2.93 | 1.41 | |
ROIC | -0.15 | -0.2 | 0.86 | -0.38 | -0.18 | |
Return on tangible assets | -0.17 | -0.19 | 0.31 | -0.49 | -0.09 | |
Graham Net | -0.55 | -1.23 | 0.19 | 0.01 | 0.5 | |
Working capital | 8.89M | 10.8M | 7.89M | 4.62M | 10.85M | |
Tangible asset value | 18.72M | 13M | 5.42M | 1.6M | 9.49M | |
Net current asset value | 3.77M | -1.11M | 5.3M | 1.53M | 9.47M | |
Invested capital | 0.45 | 0.48 | 0.24 | 0 | 0 | |
Average receivables | 438K | 410.5K | 292.5K | 145.5K | 7.5K | |
Average payables | 2.2M | 2.02M | 1.72M | 1.31M | 1.12M | |
Average inventory | 887.5K | 1.03M | 1.15M | 564K | 5.5K | |
Days sales outstanding | 90.89 | 110.36 | 0 | 5.34 | 0 | |
Days payables outstanding | 316.82 | 507.18 | 120.17 | 70.28 | 0 | |
Days of inventory on hand | 138.24 | 292.87 | 96.02 | 0.64 | 0 | |
Receivables turnover | 0.99 | 0.82 | 0 | 16.87 | 0 | |
Payables turnover | 0.28 | 0.18 | 0.75 | 1.28 | 0 | |
Inventory turnover | 0.65 | 0.31 | 0.94 | 141.09 | 0 | |
ROE | -0.25 | -0.34 | 0.37 | -0.42 | -0.07 | |
Capex per share | -0.02 | -0.01 | -0.01 | 0 | 0 |
ACRX Frequently Asked Questions
What is AcelRx Pharmaceuticals, Inc. stock symbol ?
AcelRx Pharmaceuticals, Inc. is a US stock , located in Hayward of Ca and trading under the symbol ACRX
What is AcelRx Pharmaceuticals, Inc. stock quote today ?
AcelRx Pharmaceuticals, Inc. stock price is $0.922 today.
Is AcelRx Pharmaceuticals, Inc. stock public?
Yes, AcelRx Pharmaceuticals, Inc. is a publicly traded company.